Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) went up by 7.89% from its latest closing price compared to the recent 1-year high of $10.57. The company’s stock price has collected 6.53% of gains in the last five trading sessions. Press Release reported 0 hour ago that Spectrum Pharmaceuticals Announces Two Presentations for Poziotinib at ESMO Virtual Congress 2020
Is It Worth Investing in Spectrum Pharmaceuticals, Inc. (NASDAQ :SPPI) Right Now?
Plus, the 36-month beta value for SPPI is at 2.22. Opinions of the stock are interesting as 3 analysts out of 5 who provided ratings for Spectrum Pharmaceuticals, Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 2 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $10.75, which is -$4.24 below the current price. SPPI currently public float of 104.39M and currently shorts hold a 6.02% ratio of that float. Today, the average trading volume of SPPI was 2.58M shares.
SPPI’s Market Performance
SPPI stocks went up by 6.53% for the week, with a monthly jump of 12.17% and a quarterly performance of 45.21%, while its annual performance rate touched -52.14%. The volatility ratio for the week stands at 6.24% while the volatility levels for the past 30 days are set at 5.85% for Spectrum Pharmaceuticals, Inc.. The simple moving average for the period of the last 20 days is 6.65% for SPPI stocks with a simple moving average of 15.26% for the last 200 days.
Analysts’ Opinion of SPPI
Many brokerage firms have already submitted their reports for SPPI stocks, with Guggenheim repeating the rating for SPPI by listing it as a “Neutral.” The predicted price for SPPI in the upcoming period, according to Guggenheim is $13 based on the research report published on December 26th of the previous year 2019.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see SPPI reach a price target of $4, previously predicting the value of $17. The rating they have provided for SPPI stocks is “Neutral” according to the report published on December 26th, 2019.
B. Riley FBR gave a rating of “Buy” to SPPI, setting the target price at $18 in the report published on November 27th of the previous year.
SPPI Trading at 16.00% from the 50-Day Moving Average
After a stumble in the market that brought SPPI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -59.89% of loss for the given period.
Volatility was left at 5.85%, however, over the last 30 days, the volatility rate increased by 6.24%, as shares surge +13.37% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +23.62% upper at present.
During the last 5 trading sessions, SPPI rose by +6.53%, which changed the moving average for the period of 200-days by -50.75% in comparison to the 20-day moving average, which settled at $4.00. In addition, Spectrum Pharmaceuticals, Inc. saw 16.48% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at SPPI starting from McGahan Keith M, who sold 250 shares at the price of $3.71 back on Aug 12. After this action, McGahan Keith M now owns 248,769 shares of Spectrum Pharmaceuticals, Inc., valued at $928 using the latest closing price.
McGahan Keith M, the Chief Legal Officer of Spectrum Pharmaceuticals, Inc., sold 294 shares at $4.03 during a trade that took place back on Aug 11, which means that McGahan Keith M is holding 249,019 shares at $1,183 based on the most recent closing price.
Stock Fundamentals for SPPI
The total capital return value is set at -58.19, while invested capital returns managed to touch -56.88. Equity return is now at value -77.70, with -57.00 for asset returns.
Based on Spectrum Pharmaceuticals, Inc. (SPPI), the company’s capital structure generated 2.13 points at debt to equity in total, while total debt to capital is 2.09.